Nebivolol in Patients With Systolic Stage 2 Hypertension

Completed · Phase 4 · Has a placebo group

Conditions studied: Hypertension

In brief

The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.

Key facts

Study ID

NCT01057251

Run by

Forest Laboratories

People needed

433

Starts

2010-03-01

Expected to finish

2011-01-01

Last updated by the study team

2012-01-11

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• male of female, 18 to 64 years of age at screening
• mean seated heart rate at least 60 bpm
• diagnosed systolic stage 2 hypertension
• unremarkable physical exam findings

You may not qualify if…

• high risk due to secondary hypertension or former stage 3 hypertension by JNC6
• concurrent conditions (reno, cardiovascular, obesity, thyroid, etc)
• currently taking medication that cannot be stopped during the course of the study
• participating other clinical trials
• member of the study center personnel
• documented drug abuse
• contra indication to beta blocker
• abnormal lab finding
• poor compliance
• other conditions judged by investigator that is not suitable for the study

Where it is running

• Forest Investigative Site 008 — Foley, Alabama, United States
• Forest Investigative Site 021 — Montgomery, Alabama, United States
• Forest Investigative Site 006 — Chino, California, United States
• Forest Investigative Site 002 — Long Beach, California, United States
• Forest Investigative Site 004 — Los Angeles, California, United States
• Forest Investigative Site 020 — Temecula, California, United States
• Forest Investigative Site 028 — Coral Gables, Florida, United States
• Forest Investigative Site 014 — Daytona Beach, Florida, United States
• Forest Investigative Site 001 — Fort Lauderdale, Florida, United States
• Forest Investigative Site 037 — Fort Lauderdale, Florida, United States
• Forest Investigative Site 033 — Hialeah, Florida, United States
• Forest Investigative Site 026 — Jacksonville, Florida, United States
• Forest Investigative Site 017 — Miami, Florida, United States
• Forest Investigative Site 010 — Miami, Florida, United States
• Forest Investigative Site 030 — Orlando, Florida, United States
• Forest Investigative Site 009 — Atlanta, Georgia, United States
• Forest Investigative Site 031 — Augusta, Georgia, United States
• Forest Investigative Site 039 — Meridian, Idaho, United States
• Forest Investigative Site 007 — Auburn, Maine, United States
• Forest Investigative Site 038 — Baltimore, Maryland, United States
• Forest Investigative Site 011 — Baltimore, Maryland, United States
• Forest Investigative Site 029 — Prince Frederick, Maryland, United States
• Forest Investigative Site 023 — Paw Paw, Michigan, United States
• Forest Investigative Site 005 — Florissant, Missouri, United States
• Forest Investigative Site 041 — Las Vegas, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.